Wang Xiaodong has reported significant transactions involving American Depositary Shares (ADS) of BeOne Medicines Ltd., according to a recent SEC filing. This update is important as it reflects ongoing changes in ownership and management strategies within the pharmaceutical preparations sector.

Wang Xiaodong is associated with BeOne Medicines Ltd., a company focused on pharmaceutical preparations. The company operates under the Central Index Key (CIK) number 0001651308 and was previously known as BeiGene, Ltd. The latest filing was made on October 29, 2026, and is part of a series of recent filings that detail ownership changes and transactions.

The recent filing indicates that on October 27, 2026, Xiaodong engaged in multiple transactions involving ADS. The report states, "The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026." This plan allows for the structured sale of shares, ensuring compliance with insider trading regulations.

In total, Xiaodong reported the sale of several shares, including:

  • 31,028 ADS sold at an average price of $36.90
  • 8,880 ADS sold at prices ranging from $355.08 to $356.04
  • 1,440 ADS sold at prices ranging from $356.13 to $357.09
  • 1,239 ADS sold at prices ranging from $357.19 to $357.95
  • 1,681 ADS sold at prices ranging from $358.24 to $359.23
  • 3,280 ADS sold at prices ranging from $359.37 to $360.33
  • 6,903 ADS sold at prices ranging from $360.41 to $360.97
  • 6,903 ADS sold at prices ranging from $365.88 to $366.45

Following these transactions, Xiaodong's holdings include a total of 4,588,113 shares directly owned and 1,025,063 shares indirectly owned through family trusts and other entities.

This update may impact investors and analysts closely monitoring BeOne Medicines and its market position. The active management of shares by Xiaodong could signal strategic shifts within the company, particularly as it navigates a competitive landscape in the pharmaceutical sector.

Looking ahead, the filing does not specify what actions may follow these transactions or if there will be further disclosures regarding Xiaodong's investment strategies.